Researchers at Mount Sinai Hospital in New York have presented the results of clinical trials of the world's first universal vaccine against broad-spectrum influenza virus strains and subtypes.
According to Lenta.ru, the scientists' research was published in the journal Nature Medicine.The new vaccine is based on chimeric hemagglutinin (HA) and can eliminate the need for annual revaccination.The safety and immunogenicity of the vaccine were assessed in 65 volunteers. It has been shown to produce a strong immune response that lasts for at least 18 months.